Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT04577404 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT04577404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04577404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
Shionogi
Phase
Phase 3
Overall status
Completed
Start date
October 29, 2020
Completion date
August 9, 2023
Enrollment
124 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)